Novartis readies reps for new launches

Share this article:
Novartis is boosting its sales force size ahead of anticipated drug launches, the industry trade group, the National Association of Pharmaceutical Sales Representatives (NAPSR) said.

The drugmaker penned a recruitment ad agreement with NAPSR, as the company looks to fill “nearly a thousand sales positions,” according to a release.

Calls to Novartis to obtain further details of the agreement went unreturned at press time.

Novartis is anticipating the approval of Galvus (type 2 diabetes) and Exforge (for hypertension) before the end of 2007's first quarter, chief marketing officer Kurt Graves said during UBS' Global Life Sciences conference in September.

“What we don't want to tell you is how we have set up our field force,” he said. “Every pharma company needs to come up with innovative go-to market strategies,” to be successful.

Nancy Lurker, SVP, chief marketing officer, said Novartis' efforts will undergo changes in light of these launches.  

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?